Megestrol acetate
Brand names: Megace
A synthetic progestogen used in the palliative treatment of hormone-responsive breast and endometrial cancer and as an appetite stimulant in cancer- or AIDS-related cachexia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It exerts progestogenic and anti-oestrogenic effects on hormone-sensitive tissue and stimulates appetite through incompletely understood central and metabolic actions.
Prescribing in practice
- It increases the risk of venous thromboembolism, so assess thrombotic risk and remain alert to signs of clotting during treatment.
- Prolonged use can suppress the adrenal axis, and abrupt withdrawal after long courses may unmask adrenal insufficiency.
- Avoid in pregnancy and use with caution in patients with a history of thromboembolic disease or diabetes.
Monitoring
Monitor weight, glycaemic control, blood pressure and for symptoms of thromboembolism or adrenal suppression during prolonged therapy.
Counselling the patient
- Report leg swelling or pain, breathlessness or chest pain promptly.
- Do not stop long-term treatment suddenly without medical advice.
- Weight gain is an expected and sometimes intended effect when used for appetite.
Evidence & guidelines
Megestrol acetate is an established hormonal option in advanced breast and endometrial cancer and for appetite stimulation in cachexia, as reflected in oncology practice and the SPC.
Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS